Entering text into the input field will update the search result below

Regeneron Pharmaceuticals: Undervalued Cash Generating Machine

Cappuccino Finance profile picture
Cappuccino Finance


  • REGN has a strong economic moat protected by technology and patents.
  • Profitability and strength of balance sheet are well above industry average.
  • Market is overestimating the impact of tapering sales of their COVID treatment and potential biosimilars to Eylea.
  • Current stock price offers 60-140% upside.

Multi ethnic, female team studying DNA mutations. Using microscope in protective workwear

yalax/iStock via Getty Images

Investment Thesis

Regeneron Pharmaceuticals (NASDAQ:REGN) is a biotechnology company with commercialized medicines and treatments for eye diseases, allergic and inflammatory diseases, cancer, and cardiovascular diseases. REGN presents a great opportunity for investors because:

  1. The market is

This article was written by

Cappuccino Finance profile picture
I believe in fundamental analysis and disciplined market research. I have strong quant background with a Ph.D. (Chemical Engineering, University of California, Santa Barbara) in model predictive control and an MBA (Jones School of Business, Rice University). My primary focus is to identify 1) small cap companies with strong fundamentals and growth potential, 2) large cap companies going through temporary set-backs, and 3) stable companies with solid dividend yields and growth potential.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of REGN either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (50)

Cappuccino Finance profile picture
Here is my stock chat video on Regeneron. I thought some of you would enjoy it. Have a nice weekend! https://youtu.be/rmrEyaccZz8
I have been holding $REGN for years and will continue...
dukemorty profile picture
The REGN investment thesis may get substantially better for two primary reasons.

(1) INCREASING MANUFACTURING CAPACITY: Roche/Regeneron collaboration to significantly increase manufacturing capacity and supply by 3.5x....If my math is correct, this translates to an estimated 700k dose capacity per month --- or up to 2.1MM doses per QTR.

(2) 50% LOWER DOSE SIZE: Potential Authorization for 50% smaller dosage....e.g. from 2400mg to 1200mg. These factors set the stage for robust broad global distribution and sales of its REGN-COV2 antibody cocktail that potentially far exceed current analyst estimates.

Coupled with over $6B in Cash, and what appears to be a healthy drug pipeline and low PE....REGN is in a compelling position to generate positive returns.
Cappuccino Finance profile picture
@dukemorty Thank you for the insight. Certainly great news! Long REGN!!
HiSell profile picture
Good article, I’d prefer to use a much higher WACC of 8 to 10% as there is no debt on its balance sheet.
Puche profile picture
@HiSell, you may want to take another look at REGN's most recently filed balance sheet. It shows just under $2 BILLION of debt. Just thought you may want to get your facts correct.

Just my two cents. Good luck to you!
Toucan bird profile picture
Good analysis, thanks!

Quick question, maybe I missed it, but could you quantify how much of a slowdown of revenue growth from Eylea due to competition from biosimilars you modeled?

I know it all rolls up to your base 10% EBITDA growth projection, just curious if you put pen to paper on Dupixent growth vis-a-vis Eylea shrinkage.
Cappuccino Finance profile picture
@Toucan bird Thank you for reading my article. I thought it might be worth sharing my modeling philosophy for future reference as well. My response is long.

There are a quite few literature about the economy of biosimilars (www.ncbi.nlm.nih.gov/...). Based on those, these are reasonable basic assumptions you can make 1) developing biosimilars are time consuming (can take 7-8 years) and not always successful, 2) even with successful development, manufacturing and distribution are challenging, and 3) if a company achieves all these, the successful biosimilars can take up about 10% of market share (on average).

Based on those, I made the worst scenario for REGN: 1) successful biosimilars appear for whole portfolio of REGN immediately and 2) those biosimilars immediately take 10% of market share. That give me the 10% growth instead of historical 20%. One probably can argue that this is unlikely scenario, and too conservative assumption for REGN. Hope what I did is clear.

Usually, the more variables one includes in the model, the higher probability of the model to not work properly, unless the person has very accurate data/measurements for the variables. Same thing as the more parts in the machine, the higher chance of the machine to break. :)

I think there is too much uncertainty if one tries to predict the revenue of each drug for next several years. Therefore, I thought it would be better to treat the portfolio as one variable. Have a fun investing!
Puche profile picture
@Toucan bird just a quick fyi.....Dupixent TAM is materially larger than Eylea's TAM on a US and WW basis.

Though REGN does not record all the revenues for Dupixent and Eylea on a WW basis, way back when Dupixent was first being launched I had estimated that Dupixent's WW revenues would eventually exceed $10 BILLION. I continue to believe that pie in the sky estimate is still a possibility. Please remember that REGN does NOT record all the WW sales based on the accounting they follow.

Just my two cents. Slow and steady! Good luck to all!
Toucan bird profile picture
@Puche I’ll see your two cents and raise you two!

From Sanofi in July:
Dupixent's sales are now annualizing at €5 billion, Sibold said on the Thursday conference call. Sanofi has set a €10 billion annual sales goal for the drug, and CEO Hudson said Thursday that the drug is still “only at the beginning of its journey.”
With only 6% penetration in atopic dermatitis, new approved indications rolling in and patent protection into the 2030’s, $10 Billion sounds imminent. 50% of Dupixent’s US profits + 40% of its outside US profits = a ton of cash to reward shareholders today and, by investing in their pipeline for continued scientific breakthroughs, tomorrow.

Appreciate and agree with your bullish view of the stock and the management team. My entry point is much higher than yours, but I’ve set aside shares that I hope to have the discipline to hold for 10 years. If I can resist the urge to take profits I think my kids will thank me one day.
A WACC of 3,7%....not hard to get such valuations then...
A lot of insider selling. Morningstar fair value a conservative $570. On August 18th it was reported the CEO sold 200,000 shares. How does one factor in all the insider selling this year if you are convinced in your huge upside potential? Walking away from 60% or more in additional cash on a 200K shares is huge amount of money...
Cappuccino Finance profile picture
@strendic I think insider trading is hard to judge, and the context matters a lot (and we never know the whole story). In Lonard Schleifer's case, he exercised 400,000 share at cost of $52.03 per share on August 09th, and he sold the half of them (200,000) on August 18th for $650.03 (total amount of $130 M). $130 M is a lot of money, but it's only about 0.2% of the market cap. Also, institutional holders increased their shares about 2.31% during the last three months, which is certainly a positive sign. I wouldn't read too much into it other than he took nice sum of money after hard work.

If you are interested in, there is the insider transaction section at the bottom of this finviz.com page. finviz.com/...
Good luck investing!
@Justin J. Lee Thanks on the reply. REGN has been on my watchlist and I hope to make it part my pharma portfolio if / when it reaches my target price range. Kind regards to you.
Cappuccino Finance profile picture
@strendic Thank you, and you are very welcome. Please feel free to share if you find great opportunities in health care or pharma (or any sector). Happy to learn more. Have a fun investing!
Eylea biosimilar competition puts ceiling on stock price.

Expect that to change as other products ramp up & Eylea carries on.
Cappuccino Finance profile picture
@Willow Point Yep, their impressive pipeline will bloom, and hope stock price to follow!
BM Cashflow Detective profile picture
The future depends on what we buy today.

I'm long $REGN

Hakuna Matata!
Cappuccino Finance profile picture
@BM Cashflow Detective Agree. Trying my best to make right decisions. Lion king is one of my favorite movie. Haha.
GWith profile picture
Not easy to buy when a stock is sinking but this feels like an opportunity to add at a very reasonable price.

Don't think the company was counting on resilient REGN-COV2 sales as part of their long-term strategy. More like a short-term phenomenon while joining the fight against the pandemic.

In addition to their established drugs,they are making real headway in oncology. Plus they have some potential moonshots out there, such as the obesity work.

Always going to be headwinds in pharma and the day to day market is impossible to predict. But today's investors will likely feel very good about their decision a year or two down the road.
Cappuccino Finance profile picture
@GWith I completely agree. REGN is really well run company in many different aspects, as you mentioned. Long REGN!
Dinjax profile picture
@Justin J. Lee good analysis. It does seem like the market overreacted to the Merck news; it's down $50/share since 10/1 which lopped off >$5.2B in market cap. Even though REGN-COV2 sales have a good chance of continuing I like your conservative approach of eliminating them for your valuation calcs. By almost any metric shares are way undervalued.

It could be a great time for another buyback program.
Cappuccino Finance profile picture
@Dinjax Yes, I had to re-check DCF calculation a couple of times. I thought I missed something. Hope the market realizes this gem soon. Long REGN!
Rode Regeneron from 460 to 650 this summer and I'll definitely rebuild my position soon. (And I didn't sell because it reached its fair value, it was purely a trade due to the market downturn.)
Puche profile picture
I thought this was a very well thought out and presented article. Then again, as the SA community knows, I’v been long since before Eylea was named or approved. I expect to be a shareholder 10+ years from now.

I, too, believe REGN is miss priced stock by the Street for many of the reasons the Contributor pointed out plus additional ones that I’ve written about in the past.

REGN’s oncology pipeline is dramatically undervalued and Libtayo as a foundational oncology drug is only getting started. Furthermore, because of changes in the Sanofi’s agreement, REGN will keep a much larger portion of the revenues and profits of many of its future drugs under development.

All just my two cents. Slow and steady! Good luck to all!
Cappuccino Finance profile picture
@Puche Yes! Buy the right stock, and hold it forever. I think REGN really has bright future ahead. Strong pipeline, profitable, balance sheet. Thank you for all the insights you brought for pipeline and new agreement with Sanofi!
Puche profile picture
@Justin J. Lee thanks! The past for REGN has been pretty incredible for the past 15+ years and counting!

By the way, the strong balance sheet gives them plenty of optionality. I expect them after they get through the major lab expansion they are executing to start a multi-year expansive buyback program. If the stock stays this cheap look for a $5 billion+ multi-year program to be announced within the next 18 months or so.

My two additional cents. Slow and steady! Good luck again to you!
Cappuccino Finance profile picture
@Puche Seems like you know a lot about REGN. This is one of my main reasons to publish articles on Seeking Alpha. Learning new aspect every time. Thank you! Slow and Steady, indeed!
It’s time for REGN to split now.
Cappuccino Finance profile picture
@Prospective_Spark I think that would be nice. It will certainly make the stock more affordable/attractive. Long REGN!
Puche profile picture
@Justin J. Lee IMO a stock split is not likely as Leonard would prefer to have large long term institutional investors and employees rather than the more volatile retail investor. My two cents.

Slow and steady! Good luck to all!
Dinjax profile picture
@Prospective_Spark while not an academic study, this research shows that splits generally don't increase share prices, except for companies with low/sell analyst ratings.


Other studies have found similar results.

REGN has 14 buy, 2 overweight and 9 hold ratings with nothing lower than hold so its analyst rating is relatively high.
ray69 profile picture
Good conservative valuation.
What the market does in the short term - unknowable!
Cappuccino Finance profile picture
@ray69 Thank you! Long REGN!
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!

About REGN

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on REGN

Related Stocks

SymbolLast Price% Chg
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.